Although pharmacologic inhibition of Nrp1 also targets tumor- and endothelial-Nrp1, genetic ablation of Nrp1 solely from microglia and macrophages decreased tumor volume and vascularity to the extent seen with the pharmacological treatment (Figure 2), suggesting that a critical role for Nrp1 in this setting is via signaling to/from the GAMs. The gene discussed is NRP1; the disease is neoplasm.